Literature DB >> 26966413

Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis.

W B Liu1, J F Wu1, Y Du1, G W Cao1.   

Abstract

Here, we present the basic concept and theoretical framework of a scientific hypothesis called Cancer Evolution-Development ("Cancer Evo-Dev"), based on our recent studies of the molecular mechanisms by which chronic infection with the hepatitis B virus induces hepatocarcinogenesis, together with related advances in that field. Several aspects central to our hypothesis are presented: ■ Immune imbalance-caused by the interaction of genetic predispositions and environmental exposures such as viral infection-is responsible for the maintenance of chronic non-resolving inflammation. Non-resolving inflammation promotes the occurrence and progression of cancers, characterized by an evolutionary process of "mutation-selection-adaptation" for both viruses and host cells.■ Under a microenvironment of non-resolving inflammation, proinflammatory factors promote mutations in viral or host genomes by transactivation of the expression of cytidine deaminases and their analogues. Most cells with genomic mutations and mutated viruses are eliminated in the competition for survival in the inflammatory microenvironment. Only a small percentage of the mutated cells that alter their survival signal pathways and exhibit the characteristics of "stem-ness" can survive and function as cancer-initiating cells.■ Cancers generally develop with properties of "backward evolution" and "retro-differentiation," indicating the indispensability of stem-like signal pathways in the evolution and development of cancers. The hypothesis of Cancer Evo-Dev not only lays the theoretical foundation for understanding the mechanisms by which inflammation promotes the development of cancers, but also plays an important role in specific prophylaxis, prediction, early diagnosis, and targeted treatment of cancers.

Entities:  

Keywords:  Hepatocarcinogenesis; evolution; hepatitis B virus; inflammation; mutations

Year:  2016        PMID: 26966413      PMCID: PMC4754069          DOI: 10.3747/co.23.2836

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  55 in total

1.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: symbionts and immunopathology in chronic diseases: insights from evolution.

Authors:  P W Ewald
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

2.  Long-term mutation rates in the hepatitis B virus genome.

Authors:  C Hannoun; P Horal; M Lindh
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

3.  RNA-dependent DNA polymerase in virions of RNA tumour viruses.

Authors:  D Baltimore
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

4.  Hepatitis B virus core promoter mutations contribute to hepatocarcinogenesis by deregulating SKP2 and its target, p21.

Authors:  Yuehua Huang; Shuping Tong; Andrew W Tai; Munira Hussain; Anna S F Lok
Journal:  Gastroenterology       Date:  2011-06-24       Impact factor: 22.682

5.  Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.

Authors:  Jianhua Yin; Nan Li; Yifang Han; Jie Xue; Yang Deng; Jie Shi; Weixing Guo; Hongwei Zhang; Hongyang Wang; Shuqun Cheng; Guangwen Cao
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

6.  HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations.

Authors:  Qi Zhang; Jianhua Yin; Yuwei Zhang; Yang Deng; Xiaowei Ji; Yan Du; Rui Pu; Yifang Han; Jun Zhao; Xue Han; Hongwei Zhang; Guangwen Cao
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

7.  Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.

Authors:  S R Lewin; R M Ribeiro; T Walters; G K Lau; S Bowden; S Locarnini; A S Perelson
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

8.  Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.

Authors:  Jean-Pierre Vartanian; Michel Henry; Agnès Marchio; Rodolphe Suspène; Marie-Ming Aynaud; Denise Guétard; Minerva Cervantes-Gonzalez; Carlo Battiston; Vincenzo Mazzaferro; Pascal Pineau; Anne Dejean; Simon Wain-Hobson
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

9.  Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression.

Authors:  Toshiyuki Morisawa; Hiroyuki Marusawa; Yoshihide Ueda; Akio Iwai; Il-mi Okazaki; Tasuku Honjo; Tsutomu Chiba
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

10.  Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development.

Authors:  Wing-Kit Yip; Alfred Sze-Lok Cheng; Ranxu Zhu; Raymond Wai-Ming Lung; Daisy Pui-Fong Tsang; Suki Shuk-Kei Lau; Yangchao Chen; Jonathan Gabriel Sung; Paul Bo-San Lai; Enders Kai-On Ng; Jun Yu; Nathalie Wong; Ka-Fai To; Vincent Wai-Sun Wong; Joseph Jao-Yiu Sung; Henry Lik-Yuen Chan
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

View more
  3 in total

1.  Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.

Authors:  Huaxin Zhu; Hengyang Ouyang; Xinyi Pan; Zhixiong Zhang; Jiacong Tan; Nianzu Yu; Meihua Li; Yeyu Zhao
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

2.  ASF1B promotes cervical cancer progression through stabilization of CDK9.

Authors:  Xinjian Liu; Jingwei Song; Yenan Zhang; Huiquan Wang; Hongzhi Sun; Xiaomin Feng; Min Hou; Guo Chen; Qi Tang; Minjun Ji
Journal:  Cell Death Dis       Date:  2020-08-26       Impact factor: 8.469

Review 3.  Role of Angiopoietins in Development of Cancer and Neoplasia Associated with Viral Infection.

Authors:  Xiaolan Yu; Fengchun Ye
Journal:  Cells       Date:  2020-02-18       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.